Effect of high versus low dose of human recombinant erythropoietin on the Anemia of prematurity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711201162N13

Enrollment

Registered

2009-06-07

Start date

2001-05-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia of prematurity. Anaemia of prematurity

Interventions

Intervention 1: Group 1 received erythropoietin 500 unite/kg twice in week along with supplemental iron. Intervention 2: Group 2 received erythropoietin 500 unite/kg once in week along with supplement

Group 1 received erythropoietin 500 unite/kg twice in week along with supplemental iron

Group 2 received erythropoietin 500 unite/kg once in week along with supplemental iron

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Gestational age less than 34 weeks, breast milk feeding, hematocrit <30% when infant age is between 2 to 3 weeks or HCT<25% when infant age is more than 3 weeks. Exclusion criteria: Infants with hemolytic anemia, active bleeding or congenital malformation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hemotocrite and reticulocyte count. Timepoint: the beginning, third day and one week after the end of treatment. Method of measurement: venous sampling and laboratory measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ashraf mohammadzadeh

Neonatal Research Center

mohamadzadeha@mums.ac.ir+98 51 1852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026